Racura Oncology Receives Approval for Phase 1 Trial of RC220 Combination Therapy in EGFR-Mutant Lung Cancer
核心洞察
Racura Oncology (搜索) has received governance approval from Monash Health for its HARNESS-1 Phase 1a/b trial testing RC220 in combination with osimertinib for EGFR (搜索)-mutant non-small cell lung cancer.
The trial will enroll 12-40 patients using ctDNA screening and Bayesian dose escalation to determine maximum tolerated dose, with site initiation training scheduled for March 23, 2026.
RC220 is an RNA/DNA G4 (搜索) binder designed to enhance efficacy and safety in combination therapy, addressing resistance to osimertinib in lung cancer patients.
Racura Oncology (搜索) has achieved a significant regulatory milestone with the governance approval of its HARNESS-1 Phase 1a/b trial from Monash Health, clearing the path for testing RC220 in combination with osimertinib for patients with EGFR (搜索)-mutant non-small cell lung cancer (NSCLC). The approval represents a critical step forward for the company's lead candidate as it advances into human trials targeting a significant unmet medical need in lung cancer treatment.
Trial Design and Patient Population
The HARNESS-1 trial will employ an innovative design incorporating ctDNA screening and an accelerated single-patient dose escalation cohort. The study plans to enroll between 12 and 40 patients in the initial phase, utilizing Bayesian dose escalation methodology to determine the maximum tolerated dose. Following dose determination, a Phase 1b expansion cohort will recruit up to 40 additional patients.
Site initiation training is scheduled for March 23, 2026, with first patient recruitment anticipated shortly thereafter. Four additional trial sites are planned for activation beyond the initial Monash Health location.
Mechanism of Action and Therapeutic Rationale
RC220 is described as an RNA/DNA G4 (搜索) binder, designed to enhance both efficacy and safety when used in combination therapy. The compound specifically targets EGFR (搜索)-mutant NSCLC and aims to address resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor that represents standard-of-care treatment for this patient population.
The development of RC220 builds upon prior collaboration with Emory University, which studied the compound in osimertinib-resistant NSCLC models, strengthening the preclinical understanding of its potential therapeutic benefits.
Broader Clinical Development Program
The HARNESS-1 trial approval follows Racura's December 2025 quarterly report, which highlighted expanded RC220 clinical programs extending beyond NSCLC to include acute myeloid leukemia. The company is also developing a cardioprotection blood test for use in its RAC-010 (搜索) CPACS trial, aiming for earlier clinical readouts.
Financial Position and Intellectual Property
Racura ended the December 2025 quarter with $20.94 million in cash, providing a funding runway through 2027. The company secured previous funding through private placement and option conversions. Intellectual property filings for the (E,E)-bisantrene isoform offer potential protection for up to 20 years, strengthening the company's competitive position.
The HARNESS-1 trial approval represents a key operational milestone for Racura Oncology (搜索) as it advances RC220 into human trials. While early-stage development risks remain, the company's sustained funding and expanding research collaborations provide a supportive foundation for continued clinical development in addressing unmet needs in lung cancer treatment.